TAB3 and hepatocellular carcinoma: It was reported that the levels of miRNA-26b were dramatically decreased in HCC tissues, and enhancing miR-26b expression possessed the NF-κB inhibitory effect via targeting TAK1 and TAB3, thus attenuating HCC progression (29).